Medpace

Q2 FY2026 EarningsQ2 FY26 revenue reached $707.3M, up 17.2% YoY, primarily driven by growth in Metabolic and Oncology segments. Net income rose 34.5% YoY to $121.4M, with diluted EPS at $4.25 (+37.1% YoY), benefiting from share repurchases and lower stock-based compensation. Backlog grew 4.9% YoY to $3.01B, with a net book-to-bill ratio of 1.12x. Operating margin improved to 20.8%, while the effective tax rate dropped to 20.0% due to increased foreign-derived deduction benefits.